Eli Lilly plans low-cost launch strategy for new diabetes drugs

Don't expect Eli Lilly to pump up its sales force as new diabetes drugs make their debuts over the next three years. As Lilly Diabetes President Enrique Conterno tells Bloomberg, the company ($LLY) plans to lean on its broad product portfolio to grow sales, rather than sending out legions of reps to push new drugs brand-by-brand. "I don't think the market is responsive today to putting more and more sales people focused on brands," Conterno told the news service. "We start with the patient and think of all the therapies we could have for him." Report

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.